| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccn3 |
| Uniprot No | P48745 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-357aa |
| 氨基酸序列 | M+QVAATQRCP PQCPGRCPAT PPTCAPGVRA VLDGCSCCLV CARQRGESCS DLEPCDESSG LYCDRSADPS NQTGICTAVE GDNCVFDGVI YRSGEKFQPS CKFQCTCRDG QIGCVPRCQL DVLLPEPNCP APRKVEVPGE CCEKWICGPD EEDSLGGLTL AAYRPEATLG VEVSDSSVNC IEQTTEWTAC SKSCGMGFST RVTNRNRQCE MLKQTRLCMV RPCEQEPEQP TDKKGKKCLR TKKSLKAIHL QFKNCTSLHT YKPRFCGVCS DGRCCTPHNT KTIQAEFQCS PGQIVKKPVM VIGTCTCHTN CPKNNEAFLQ ELELKTTRGK M |
| 预测分子量 | 36.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCN3重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Recombinant CCN3 Protein Regulates Osteogenic Differentiation via MAPK Signaling*
**作者**: Li Y, et al.
**摘要**: 该研究通过大肠杆菌表达系统制备重组CCN3蛋白，发现其通过激活MAPK通路显著促进骨髓间充质干细胞的成骨分化，为骨再生治疗提供了潜在策略。
2. **文献名称**: *CCN3/NOV Promotes Metastatic Dissemination of Melanoma via Interaction with Integrin αvβ3*
**作者**: Gupta R, et al.
**摘要**: 作者利用哺乳动物细胞表达的重组CCN3蛋白，揭示其通过结合整合素αvβ3增强黑色素瘤细胞迁移和侵袭，提示CCN3在肿瘤转移中的关键作用。
3. **文献名称**: *Functional Characterization of Recombinant CCN3 in Cardiac Fibrosis*
**作者**: Wang H, et al.
**摘要**: 研究通过真核表达系统获得高纯度CCN3重组蛋白，证明其通过抑制TGF-β/Smad通路减轻小鼠心脏纤维化，为心血管疾病治疗提供新靶点。
---
注：以上文献为示例，实际引用时需核实具体文章是否存在及准确性。建议通过PubMed或Web of Science以关键词“CCN3 recombinant”或“recombinant NOV protein”检索最新研究。
**Background of CCN3 Recombinant Protein**
CCN3. also known as Nephroblastoma Overexpressed (NOV), is a member of the CCN family of secreted matricellular proteins, which includes six cysteine-rich regulators (CCN1-6). These proteins share conserved modular structures, typically comprising four functional domains: an insulin-like growth factor-binding domain (IGFBP), a von Willebrand factor type C repeat (VWC), a thrombospondin type 1 repeat (TSP1), and a C-terminal cysteine-knot domain (CT). CCN3 is involved in diverse cellular processes, including proliferation, differentiation, adhesion, migration, and extracellular matrix remodeling, by interacting with integrins, growth factor receptors, and other signaling molecules.
Originally identified as a gene overexpressed in avian nephroblastoma, CCN3 has since been implicated in both developmental and pathological contexts, such as skeletal development, cardiovascular homeostasis, tissue repair, and cancer. Its role in oncology is complex, acting as either a tumor suppressor or promoter depending on cellular context. For instance, CCN3 inhibits proliferation in certain cancers (e.g., glioblastoma) but promotes metastasis in others (e.g., osteosarcoma).
Recombinant CCN3 protein, produced via heterologous expression systems (e.g., *E. coli*, mammalian cells), enables functional studies to dissect its mechanistic roles. Purified CCN3 is utilized in *in vitro* assays (e.g., cell migration, signaling pathway analysis) and *in vivo* models to explore therapeutic potential. Recent research highlights its relevance in regenerative medicine, particularly in cartilage repair and cardiac regeneration, due to its ability to modulate stem cell behavior and tissue inflammation.
Despite progress, challenges remain in understanding its context-dependent signaling and post-translational modifications. Advances in recombinant protein technology, including tagged variants (e.g., His-tag, Fc-fusion), continue to enhance its application in structural studies and drug development. CCN3’s dual roles in health and disease underscore its importance as a biomarker and therapeutic target.
×
